Saturday, July 11, 2026

Drug profile · INN

durlobactam sodium

durlobactam sodium (XACDURO (COPACKAGED)) is a beta-lactamase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — durlobactam sodium
US status
approved
Class
Route
INTRAVENOUS
Patents
0
Programs
0
Data quality
0.84

Quick answer

durlobactam sodium (XACDURO (COPACKAGED)) is a beta-lactamase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.

Key facts

INN durlobactam sodium
Brand XACDURO (COPACKAGED)
Mechanism Beta-lactamase inhibitor
Target Beta-lactamase
Route INTRAVENOUS
Formulation POWDER

Mechanism of action

Beta-lactamase inhibitor

Primary target: Beta-lactamase

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. avibactam sodium Bacterial beta-lactamase TEM inhibitor
  2. clavulanate potassium Bacterial beta-lactamase TEM inhibitor

Frequently asked questions

What is durlobactam sodium?

durlobactam sodium (XACDURO (COPACKAGED)) is a beta-lactamase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.

What is the brand name for durlobactam sodium?

XACDURO (COPACKAGED) is a marketed brand name for durlobactam sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of durlobactam sodium?

durlobactam sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.